Ipsen: Q1 sales up 11%

(CercleFinance.com) - Biopharmaceutical company Ipsen reported sales up 10.
9% to E822.4m for Q1 2024.

Growth excluding currency effects was driven by the performance of growth platforms, up 16.2%, and a growing contribution from new drugs, while Somatuline sales fell by just 1.3%.

Ipsen confirms its 2024 targets (excluding the potential impact of additional external late-stage product innovation transactions) of sales growth in excess of 6% at constant exchange rates and an operating margin of around 30%.


Copyright (c) 2024 CercleFinance.com. All rights reserved.